Trial Profile
A Phase 1b/2 Study With Gemcitabine and LY2157299 for Patients With Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 Sep 2022
Price :
$35
*
At a glance
- Drugs Galunisertib (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly and Company
- 15 Oct 2018 Results published in the British Journal of Cancer.
- 16 Jan 2017 Status changed from active, no longer recruiting to completed.
- 07 Jun 2016 Results from phase II portion of the study (n=156) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology